Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb24306 and Cevostamab in Relapsed/Refractory Multiple Myeloma
NCT05646836Phase 1Active, not recruiting
- Sponsor
- Genentech
- Start
- Mar 2023
- Primary completion
- Nov 2026
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 7
01
Overview
Phase 1, open-label trial of efbalropendekin alfa in multiple myeloma (MM) (2 arms), sponsored by Genentech. Primary endpoint: Percentage of Participants with Adverse Events at 3 years. Started Mar 2023; status: active, not recruiting.
02
Drugs
efbalropendekin alfa
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05646836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05646836.